Why D-Dimer test is Important in Severe COVID-19 Infection
SAN DIEGO, CA
Severe COVID-19 infection is associated with high morbidity and mortality with 50% of the deaths determined to be due to coagulopathy1. Studies have revealed that patients with serious infection are more likely to have COVID-19 associated coagulopathy than patients with mild infection, and those who die from COVID-19 are more likely to have met the International Society on Thrombosis and Haemostasis, criteria for disseminated intravascular coagulation compared to survivors. Elevated D-dimer at admission and markedly increasing D-dimer levels (3- to 4-fold) over time are associated with high mortality, likely reflecting coagulation activation from infection/sepsis, cytokine storm and impending organ failure2. Based on these studies and recently published guidelines from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), strongly advocate for D-Dimer testing in patients with COVID-193.
Because of the increasing number of patients with severe COVID-19 infection, labs are experiencing a spike in D-Dimer test demand. The need for improved turnaround time and for a more reliable supply chain has left many labs reevaluating their current D– Dimer testing strategy.
For further information on the Diazyme D-Dimer assay, please visit the D-Dimer product page or contact your local sales representative.
Product Page: https://www.diazyme.com/d-dimer
Contact us: https://www.diazyme.com/contact
Diazyme Laboratories, Inc., a Life Science Affiliate of General Atomics, is located in Poway, California. Diazyme uses its proprietary enzyme and immunoassay technologies to develop diagnostic test reagents run on automated chemistry analyzers and chemiluminescence instruments in user-friendly formats. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. Information regarding Diazyme's technology and products can be found on its website at www.diazyme.com
For Further Information Contact:
Abhijit Datta, Ph.D.
- Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 A Prospective Cohort Study Wichmann D, et al. Ann Intern Med. 2020. PMID: 32374815
- COVID-19 and Coagulopathy: Frequently Asked Questions Version 3.0; last reviewed June 23, 2020 https://www.hematology.org/covid-19/covid-19-and-coagulopathy
- IFCC Information Guide on COVID-19 [Internet]. IFCC Information Guide on COVID-19. 2020. Available on: https://www.ifcc.org/ifcc-news/2020-03-26-ifcc-information-guide-on-covid-19/